FGF23, fibroblast growth factor 23, 8074

N. diseases: 305; N. variants: 19
Disease: Phosphate Diabetes ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE We demonstrate that FGF23 is not capable of inducing phosphaturia via FGFR4 and that FGFR4 does not promote or mitigate renal injury in animal models of CKD. 31575945 2019
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Calcification does not occur in disorders with increased FGF23 when phosphaturia occurs in isolation and 1,25 (OH)<sub>2</sub>D is suppressed. 31122608 2019
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE The overproduction of fibroblast growth factor 23 causes a paraneoplastic syndrome characterized by hyperphosphaturia, hypophosphatemia, hypovitaminosis D, and vitamin D refractory rickets/osteomalacia, effects that disappear with tumor removal. 31261249 2019
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Fibroblast growth factor 23 (FGF23) participates in the orchestration of mineral metabolism by inducing phosphaturia and decreasing the production of 1,25(OH)<sub>2</sub>D<sub>3</sub>. 29483574 2018
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Both the phosphaturia and the TIO are due to paraneoplastic production of FGF23 (a phosphatonin) by the neoplastic cells, which are genetically characterized by rearrangements of FN1 (most often with FGFR1, and less frequently with FGF1). 29514106 2018
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE FGF23 is a bone-derived hormone that acts primarily on the kidney to induce phosphaturia and suppress synthesis of 1,25-dihydroxyvitamin D<sub>3</sub>. 27838783 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Phosphate (Pi) homeostasis is regulated by renal, intestinal, and endocrine mechanisms through which Pi intake stimulates parathyroid hormone (PTH) and fibroblast growth factor-23 secretion, increasing phosphaturia. 28246304 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or <i>α</i>-klotho levels. 29074818 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Fibroblast growth factor-23 (FGF23), a phosphaturic hormone secreted mainly by osteocytes, maintains serum phosphate levels within a tight range by promoting phosphaturia. 27942978 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE The neoplastic cells produce increased amount of FGF23 which results in TIO via uncontrolled renal loss of phosphate (phosphaturia), and consequently diminished bone mineralization.To date, ∼300 cases have been reported. 28614212 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Iron-induced hypophosphataemic osteomalacia is thought to be due to reduced degradation of FGF23, resulting in phosphaturia and reduced synthesis of 1,25-dihydroxy vitamin D. Monitoring of patients on long-term parenteral iron is recommended to avoid clinically serious adverse effects. 28203361 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 AlteredExpression disease BEFREE In normal rats, the infusion of rat recombinant FGF23 enhanced phosphaturia and increased renal FGFR1 expression; however, Klotho expression was reduced. 28515153 2017
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 AlteredExpression disease BEFREE Bone-produced fibroblast growth factor 23 (FGF23) bound to Klotho in tubule cells and intracellular phosphate concentrations are regulators of 1-α-hydroxylase activity and cause proximal tubule phosphaturia. 25618772 2016
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 AlteredExpression disease BEFREE FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. 22647968 2012
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 AlteredExpression disease BEFREE Our finding of expression of FGF23 in 75% of histologically identical tumors without known TIO confirms the reproducibility of the diagnosis of PMTMCT, even in the absence of known phosphaturia. 19609206 2009
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE The pathophysiological defect in XLH is speculated to cause an increase in a circulating phosphate regulating hormone termed phosphatonin (fibroblast growth factor 23 is the primary phosphatonin candidate), which leads to inhibition of 1alpha-hydroxylase, and simultaneously to inhibition of the sodium-phosphate transporter domain NPT2c leading to parathyroid hormone-independent phosphaturia. 18775977 2008
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Intact plasma levels of the phosphaturic protein FGF23 (fibroblast growth factor 23) were clearly elevated in some of the affected individuals, providing a possible explanation for the phosphaturia and inappropriately normal 1,25(OH)2D levels, and suggesting that DMP1 may regulate FGF23 expression. 17635744 2007
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 AlteredExpression disease BEFREE Intact plasma levels of the phosphaturic protein FGF23 were clearly elevated in two of four affected individuals, providing a possible explanation for the phosphaturia and inappropriately normal 1,25(OH)2D levels and suggesting that DMP1 may regulate FGF23 expression. 17033625 2006
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Administration of FGF-23 in vivo results in phosphaturia and an increase in prostaglandin excretion, and FGF-23 increases proximal tubule prostaglandin production in vitro. 16721588 2006
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE The lines of evidence described suggest that FGF-23 and other factors may coexist, causing hyperphosphaturia and impaired intestinal absorption of phosphate, respectively. 16369891 2006
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. 12711740 2003
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE Thus, sFRP-4 displays phosphatonin-like properties, because it is a circulating protein that promotes phosphaturia and hypophosphatemia and blunts compensatory increases in 1alpha, 25-dihydroxyvitamin D. 12952927 2003
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease BEFREE A non-PTH circulating serum factor (possibly phosphatonin) that increases FE(PO4) during CRF is also responsible for phosphaturia and hypophosphatemia in the early period following successful kidney transplantation. 11532115 2001
CUI: C0282201
Disease: Phosphate Diabetes
Phosphate Diabetes 		0.200 Biomarker disease HPO